Welcome to our dedicated page for Clover Health Investments SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clover Health Investments, Corp. (Nasdaq: CLOV) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a publicly traded Medicare Advantage and healthcare technology issuer. Clover Health files reports with the U.S. Securities and Exchange Commission that describe its Medicare Advantage insurance operations, technology platform, financial performance, risk factors, and governance.
Investors can review current reports on Form 8-K, where Clover Health announces material events such as quarterly financial results, CMS Star Ratings for its Medicare Advantage PPO and HMO plans, and board or governance changes. Some 8-K filings also reference supplemental written responses to shareholder questions, offering additional context on strategy, cohort economics, and the role of Clover Assistant and Counterpart Health in the business.
In addition to 8-Ks, Clover Health’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) typically provide detailed discussions of its Insurance segment, Medicare Advantage membership trends, non-GAAP measures such as Adjusted EBITDA and Insurance Benefits Expense Ratio, and regulatory considerations related to Medicare, CMS Star Ratings, and value-based care arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand how items such as Star Rating changes, CMS rate updates, or shifts in membership mix may affect Clover Health’s reported results. Users can also track insider transaction reports on Form 4 when they appear, to monitor equity transactions by directors and officers.
Filings are updated in near real time from the SEC’s EDGAR system, allowing investors, analysts, and other stakeholders to follow Clover Health’s evolving disclosures on Medicare Advantage performance, technology initiatives through Clover Assistant and Counterpart Health, and corporate governance developments.
Conrad Wai, an officer (CEO, Counterpart Health) of Clover Health Investments, Corp. (CLOV), reported a transaction on 09/14/2025 involving the vesting of time-based restricted stock units granted on 03/14/2022. To satisfy tax withholding when 6.25% of the original RSU grant vested, 98,412 shares of Class A common stock were automatically withheld at a price of $3.06 per share. After the withholding, the reporting person beneficially owned 1,573,425 shares directly and 1,403,701 shares indirectly (held in a trust for family benefit, of which the reporting person is co-trustee). The remaining RSUs continue to vest quarterly with final vesting on 03/14/2026, contingent on continued service.
Karen M. Soares, General Counsel & Secretary of Clover Health Investments, Corp. (CLOV), reported a routine withholding of vested restricted stock units on August 14, 2025. The Form 4 shows 7,459 shares of Class A common stock were disposed of at an implicit withholding price of $2.57 per share to cover tax obligations tied to the vesting of 6.25% of RSUs originally granted on February 14, 2022. After this withholding, the Reporting Person beneficially owns 1,469,487 shares of Class A common stock.
The filing explains the RSU schedule: the 6.25% portion vested on August 14, 2025, with the remaining time‑based RSUs vesting in equal quarterly installments of 6.25% and a final vesting date of February 14, 2026, contingent on continued service. The Form 4 was signed by an attorney‑in‑fact on behalf of Ms. Soares on August 18, 2025.
Anna U. Loengard, a director of Clover Health Investments, reported purchases of Class A common stock executed on 08/13/2025 and a reduction in previously reported beneficial ownership. The filing shows two custodial IRA purchases for the reporting person’s children: 12,000 shares at $2.60 and 14,500 shares at $2.59, held indirectly in a son’s and daughter’s IRA, respectively. The report also states the reporting person no longer has a reportable beneficial interest in 151,725 shares previously held by an ex-spouse. Following the transactions reported, Loengard beneficially owns 29,610 and 27,600 shares indirectly as noted.
Andrew Toy, who serves as both a Director and the Chief Executive Officer of Clover Health Investments (CLOV), reported that on 08/08/2025 85,535 shares of Class A common stock were automatically withheld to satisfy tax obligations when 6.25% of time-based restricted stock units (RSUs) granted on 08/08/2022 vested. The form reports a per-share price of $2.18 for the transaction. After the withholding, Mr. Toy directly beneficially owns 10,474,512 shares. The remaining RSUs continue to vest quarterly in equal 6.25% installments, with a final vesting date of 08/08/2026, subject to his continued service.
Clover Health Investments, Corp. published written responses to a selection of shareholder questions submitted before its second-quarter 2025 earnings announcement to increase engagement with its investor base. The company furnished those responses as Exhibit 99.1, and the Co‑Founder and Executive Chairman, Vivek Garipalli, provided separate written responses furnished as Exhibit 99.2. Both exhibits are furnished with the Current Report and are also available on the company’s investor relations website. The company states these materials are furnished for disclosure purposes and are not "filed" for Section 18 purposes and are not incorporated by reference into other filings except by specific reference.
Vivek Garipalli, a director and 10% owner of Clover Health Investments (CLOV), reported purchases of Class A common stock on 08/07/2025 and 08/08/2025. He acquired 415,000 shares on 08/07/2025 at a weighted average price of $2.24 and 31,980 shares on 08/08/2025 at a weighted average price of $2.17, bringing his reported direct ownership to 1,856,247 Class A shares.
Table II discloses substantial Class B common stock that converts one-for-one into Class A: 6,904,343 Class A-equivalent shares held directly, plus 11,500,000 and 72,084,543 Class A-equivalent shares held indirectly by Caesar Clover, LLC and NJ Healthcare Investments, LLC, respectively. The filing states Garipalli serves as sole manager of those LLCs.
Clover Health (CLOV) Q2 2025 10-Q snapshot
Premiums climbed 34% YoY to $469.8 m, lifting total revenue to $477.6 m, yet net medical claims surged 52% to $378.0 m, pushing the medical loss ratio to ~80.5% (71% in Q2 2024). Operating loss was $10.6 m versus prior-year profit of $7.2 m; GAAP EPS fell to –$0.02.
First-half revenue rose 34% to $939.9 m while net loss narrowed to $11.9 m (–$0.02 EPS) from $16.0 m, aided by a $2.8 m favourable prior-year claims development. Stock-based compensation remained high at $52.6 m YTD.
Cash & equivalents ended at $188.6 m, down $5.9 m YTD. Operating cash flow swung to a $10.9 m outflow (vs. $79.7 m inflow last year); investing inflows of $44.5 m offset $39.5 m used for equity-related financing. Total assets were $575 m and equity improved to $344 m.
Unpaid claims declined 11% YTD to $139.7 m; investment portfolio posted a $1.8 m unrealised gain, turning OCI positive. Weighted-average diluted shares stood at 509 m.
Management continues to expand Clover Assistant and Counterpart Health SaaS but flags medical cost inflation, RADV audit exposure and regulatory uncertainty as key risks.